If Biogen Says No, Mr. Icahn, GTO Would Take $23 Billion | GenomeWeb

If you remember anyone who used to say that biotech would never amount to anything, now's the time to make the told-you-so phone call. Biogen Idec says it is considering a possible sale of the company, and one of the interested parties is Carl Icahn, who offered at least $23 billion, according to this article in the Wall Street Journal. Biogen Idec has a market cap of about $23.5 billion.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.